Drug Profile
Eplerenone - Pfizer
Alternative Names: CGP 30083; Epoxymexrenone; Inspra; SC 66110; SelaraLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Medical University of Graz; Pfizer; Solvotrin Innovations
- Class Anti-ischaemics; Antihypertensives; Cardiovascular therapies; Heart failure therapies; Lactones; Pregnenes; Small molecules
- Mechanism of Action Aldosterone receptor antagonists; Potassium-sparing diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Hypertension
- Discontinued Chronic heart failure; Left ventricular dysfunction; Postmyocardial infarction; Primary hyperparathyroidism
Most Recent Events
- 08 Apr 2021 Discontinued - Phase-III for Chronic heart failure in Japan, Argentina, Australia, Asia, North America, Europe (PO) (Pfizer pipeline, April 2021)
- 08 Apr 2021 Discontinued - Phase-III for Postmyocardial infarction in France, Netherlands, United Kingdom, Greece, Germany, Slovakia, Hungary, Canada, Czech Republic, Poland, Spain (PO) (Pfizer pipeline, April 2021)
- 08 Apr 2021 Discontinued - Phase-II for Left ventricular dysfunction in Ireland (PO) (Pfizer pipeline, April 2021)